LUND, Sweden ,
Aug. 26, 2020 /PRNewswire/
-- Immunovia AB (publ) ("Immunovia"), today announced
that the Board of Directors has appointed Patrik Dahlen as new CEO starting November 1, 2020. Patrik
Dahlen has extensive experience as previous CEO of several
diagnostic companies and succeeds Mats
Grahn who has successfully brought the company from
development to commercial stage over the last seven years. Mats has
now been nominated as a member of the Company's board.
Patrik Dahlen is a seasoned
executive with broad international experience and brings
substantial diagnostic and international industry expertise. As
Chief Executive Officer of Dako, Patrik, carried out a major
strategic repositioning of the company as a leading supplier of
cancer diagnostics, which resulted in the acquisition by Agilent
for $2.2 billion. As President of Life Sciences at the
American company Perkin Elmer, Patrik was instrumental in building
the company's diagnostic business with a niche focus on diagnostic
systems for neonatal and prenatal screening. He has led
organizations ranging from 10 to 2000 people based in Finland, Denmark, UK and USA and has considerable public company
experience.
CEO, Mats Grahn, and the Chairman
of the Board, Carl Borrebaeck, will host a webcast to discuss
further and hold a question and answer session today. The live
webcast is scheduled to begin at 4:00 p.m.
CET on August 26, 2020.
Event Details:
To join the webinar: Register for Webinar
"Immunovia is one of a few companies that has the possibility to
fundamentally change cancer diagnostics in order to meet
significant unmet clinical needs with its cutting-edge platform
technology IMMray™. I couldn't be more honored to have been chosen
to lead the company's next growth phase. The opportunities for
Immunovia are vast, and to seize it we must continue to have a
clear focus, move our commercial initiatives with excellence and
continue to transform as we grow," says Patrik Dahlen.
"We are thrilled to welcome Patrik
Dahlen as our new CEO during this pivotal time at the
company, as we aim for a successful sales start of our first
product, which is a true milestone on our path towards the
company's vision to become a leader in early detection of complex
diseases such as cancer. Patrik has a truly solid commercial
background in the diagnostic sector and will add valuable expertise
through his proven track record of driving and expanding sales into
international markets. The Board strongly believes that Patrik has
the necessary skills, vision and determination to build on the
foundations that current CEO Mats
Grahn has successfully laid in recent years," says Carl
Borrebaeck, Chairman of Immunovia.
"I am pleased to hand over Immunovia to Patrik, whom I know as
one of the most experienced and strongest leaders in the
international diagnostics industry. Patrik is the perfect
choice for Immunovia at a time when the Company is transforming
from a development to a commercial expansion stage enterprise. I
have enjoyed every minute of the journey in building Immunovia from
world leading academic research to where it is today, an
established and successful company," says Mats Grahn.
"Mats has done a fantastic job in building Immunovia, including
the creation of the largest network of clinical experts and a
full-scale US commercial unit. With his drive and vision, he has
demonstrated the potential of advanced clinical cancer tests
thereby building shareholder value. In order to secure continued
access to Mats broad expertise and experience, the nomination
committee has decided to nominate Mats
Grahn as a board member of Immunovia at an Extra General
Meeting," Carl Borrebaeck continues.
Information about an Extra General Meeting will be published
separately during Q3 2020.
This is information that Immunovia is obliged to make public
pursuant to the EU Market Abuse Regulation. The information was
submitted for publication, through the agency of the contact person
set out above, at 8:30 CET on
August 26, 2020.
For more information, please contact:
Julie Silber, Director of
Investor Relations, Immunovia
Email: julie.silber@immunovia.com
Tel: +46 7 93 486 277
About Immunovia
Immunovia AB is a diagnostic company that is developing and
commercializing highly accurate blood tests for the early detection
of cancer and autoimmune diseases based on Immunovia's
proprietary test platform called IMMray™. Tests are based on
antibody biomarker microarray analysis using advanced
machine-learning and bioinformatics to single-out a set of relevant
biomarkers that indicate a certain disease. Thus, forming a unique
"disease biomarker signature".
The company was founded in 2007, based on cancer studies and
ground-breaking research in the Department of Immuntechnology at
Lund University and CREATE Health
Cancer Center, Sweden.
The first product, IMMray™ PanCan-d, is undergoing clinical
evaluation in some of the world's largest clinical studies for
pancreatic cancer, PanFAM-1, PanSYM-1 and PanDIA-1 and is
currently in the final validation for sales start Q4 2020.
When validated, IMMray™ PanCan-d will be the first blood-based test
for early diagnosis of pancreatic cancer on the market, with a
potential to significantly improve patient survival and
outcome.
Immunovia Dx Laboratories located in Marlborough, Massachusetts, USA and
Lund, Sweden will provide
laboratory testing services in two accredited reference
laboratories.
Immunovia's shares (IMMNOV) are listed on Nasdaq Stockholm. For
more information, please visit www.immunovia.com.
This information was brought to you by Cision
http://news.cision.com
https://news.cision.com/immunovia-ab/r/immunovia-announces-ceo-transition--appoints-patrik-dahlen-as-new-ceo,c3181074
The following files are available for download:
https://mb.cision.com/Main/13121/3181074/1297145.pdf
|
Release
|